Callan Capital Lowers stake in Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) : Callan Capital reduced its stake in Neurocrine Biosciences by 31.82% during the most recent quarter end. The investment management company now holds a total of 15,000 shares of Neurocrine Biosciences which is valued at $725,700 after selling 7,000 shares in Neurocrine Biosciences , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Neurocrine Biosciences makes up approximately 0.28% of Callan Capital’s portfolio.

Other Hedge Funds, Including , Proshare Advisors reduced its stake in NBIX by selling 9,021 shares or 11.84% in the most recent quarter. The Hedge Fund company now holds 67,146 shares of NBIX which is valued at $3,248,523. Neurocrine Biosciences makes up approx 0.04% of Proshare Advisors’s portfolio.Eam Investors reduced its stake in NBIX by selling 25,489 shares or 31.32% in the most recent quarter. The Hedge Fund company now holds 55,895 shares of NBIX which is valued at $2,793,073. Neurocrine Biosciences makes up approx 0.39% of Eam Investors’s portfolio.Woodstock Corp boosted its stake in NBIX in the latest quarter, The investment management firm added 4 additional shares and now holds a total of 19,959 shares of Neurocrine Biosciences which is valued at $1,004,736. Neurocrine Biosciences makes up approx 0.20% of Woodstock Corp’s portfolio.Capital Fund Management S.a. boosted its stake in NBIX in the latest quarter, The investment management firm added 68,711 additional shares and now holds a total of 77,121 shares of Neurocrine Biosciences which is valued at $3,919,289. Neurocrine Biosciences makes up approx 0.07% of Capital Fund Management S.a.’s portfolio.

Neurocrine Biosciences closed down -0.23 points or -0.46% at $49.31 with 4,38,000 shares getting traded on Monday. Post opening the session at $49.67, the shares hit an intraday low of $48.96 and an intraday high of $49.8 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Neurocrine Biosciences reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.49.During the same quarter in the previous year, the company posted $-0.28 EPS.

Many Wall Street Analysts have commented on Neurocrine Biosciences. H.C. Wainwright Initiated Neurocrine Biosciences on Jun 29, 2016 to “Buy”, Price Target of the shares are set at $80.

Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.

Leave a Reply

Neurocrine Biosciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Neurocrine Biosciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.